Condition: Brain Cancer · Brain Neoplasm · Glioma · Sponsor: DNAtrix, Inc.
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Arkansas for Medical Sciences (UAMS) | Little Rock, Arkansas, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| University of Minnesota Neurosurgery | Minneapolis, Minnesota, United States | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Weill-Cornell Medicine New York-Presbyterian | New York, New York, United States | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | — |
| Cleveland Clinic | Cleveland, Ohio, United States | — |
| Ohio State University James Cancer Center | Columbus, Ohio, United States | — |
| Lehigh Valley Health Network | Allentown, Pennsylvania, United States | — |
| Texas Oncology Austin-Midtown | Austin, Texas, United States | — |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02798406